Seminars in Radiation Oncology
Volume 19, Issue 4 , Pages 256-265 , October 2009

Inflammatory Breast Cancer

  • Wendy A. Woodward, MD, PhD

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Massimo Cristofanilli, MD

      Affiliations

    • Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationAddress reprint requests to Massimo Cristofanilli, MD, Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX

References 

  1. Anderson WF, Schairer C, Chen BE, et al. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9–23
  2. Bell C. In: A System of Operative Surgery. vol 2:Hartford, CT: Hale and Homser; 1814;
  3. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: A report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet. 1924;39:580
  4. Greene FL, Page DL, Fritz A, et al. Breast. In: AJCC Cancer Staging Manual. New York, NY: Springer-Verlag; 2002;p. 255–281
  5. Denoix P. Treatment of malignant breast cancer. In: Recent Results in Cancer Research. Berlin: Springer-Verlag; 1970;p. 92–94
  6. Mourali N, Muenz LR, Tabbane F, et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46:2741–2746
  7. Mourali N, Tabbane F, Muenz LR, et al. Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest. 1993;11:363–370
  8. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966–975
  9. Levine PH, Steinhorn SC, Ries LG, et al. Inflammatory breast cancer: The experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985;74:291–297
  10. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82:2366–2372
  11. Wingo PA, Jamison PM, Young JL, et al. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control. 2004;15:321–328
  12. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society; 2007;
  13. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16:3731–3735
  14. Levine PH. Factors for the development of aggressive inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004;(suppl 1):S91
  15. Swanson CA, Brinton LA, Taylor PR, et al. Body size and breast cancer risk assessed in women participating in te breast Cancer Detection Demonstration project. Am J Epidemiol. 1989;130:1133–1141
  16. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition?. Int J Cancer. 1995;62:382–385
  17. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251:1451–1455
  18. Kleer CG, van Golen KL, Braun T, et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001;14:458–464
  19. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987–993
  20. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696–1701
  21. Bukholm IK, Nesland JM, Karesen R, et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol. 1998;185:262–266
  22. Hunt NC, Douglas-Jones AG, Jasani B, et al. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch. 1997;430:285–289
  23. Siitonen SM, Kononen JT, Helin HJ, et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996;105:394–402
  24. Heimann R, Lan F, McBride R, et al. Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin. Cancer Res. 2000;60:298–304
  25. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003;88:718–725
  26. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231–5241
  27. Alpaugh ML, Tomlinson JS, Kasraeian S, et al. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002;21:3631–3643
  28. Alpaugh ML, Tomlinson JS, Ye Y, et al. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol. 2002;161:619–628
  29. Charafe-Jauffret E, Tarpin C, Bardou VJ, et al. Immunophenotypic analysis of inflammatory breast cancers: Identification of an “inflammatory signature”. J Pathol. 2004;202:265–273
  30. McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002;8:3857–3862
  31. Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma (Comparison with locally advanced disease). Cancer. 1989;64:1922–1927
  32. Harvey HA, Lipton A, Lawrence BV, et al. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982;21:42–44
  33. Nguyen DM, Sam K, Tsimelzon A, et al. Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype. Clin Cancer Res. 2006;12:5047–5054
  34. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol. 1992;10:1014–1024
  35. Van den Eynden GG, Van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004;85:13–22
  36. Aziz SA, Pervez S, Khan S, et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: A unique clinical experience. Breast J. 2001;7:398–404
  37. Riou G, Le MG, Travagli JP, et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765–1767
  38. Turpin E, Bieche I, Bertheau P, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002;21:7593–7597
  39. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer. 1989;43:201–208
  40. Guerin M, Sheng ZM, Andrieu N, et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990;5:131–135
  41. Parton M, Dowsett M, Ashley S, et al. High incidence of Her-2 positivity in inflammatory breast cancer. Breast. 2004;13:97–103
  42. Charpin C, Bonnier P, Khouzami A, et al. Inflammatory breast carcinoma: An immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res. 1992;12:591–597
  43. Sawaki M, Ito Y, Akiyama F, et al. High prevalence of Her-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer. 2006;13:172–178
  44. Foekens JA, Rio MC, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 1990;50:3832–3837
  45. Prost S, Le MG, Douc-Rasy S, et al. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer. 1994;58:763–768
  46. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004;10:6215–6221
  47. Faille A, De Cremoux P, Extra JM, et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994;69:1145–1150
  48. Resetkova E, Gonzalez-Angulo AM, Sneige N, et al. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004;101:913–917
  49. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  50. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–56
  51. van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999;5:2511–2519
  52. van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832–5838
  53. Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002;160:579–584
  54. Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93:101–110
  55. Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005;93:237–246
  56. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res. 2006;12:3249–3256
  57. Bozzetti F, Saccozzi R, Lena MD, et al. Inflammatory cancer of the breast: Analysis of 114 cases. J Surg Oncol. 1981;18:355–361
  58. Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology. 1976;121:173–176
  59. Zucali R, Uslenghi C, Kenda R, et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37:1422–1431
  60. Thames HD, Peters LJ, Withers HR, et al. Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983;9:127–138
  61. Barker JL, Montague ED, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer. 1980;45:625–629
  62. Thoms WW, McNeese MD, Fletcher GH, et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:739–745
  63. Ueno NT, Buzdar AU, Singletary SE, et al. Combined modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson center. Cancer Chemother Pharmacol. 1997;40:321–329
  64. Blumenschein G, Montague ED, Eckles NE, et al. Sequential combined modality therapy for inflammatory breast cancer. Breast. 1976;2:16–20
  65. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: Results of a combined-modality approach-M. D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990;27:94–100
  66. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg. 1994;18:87–92
  67. Buzdar AU, Singeltary SE, Booser DJ, et al. Combined modality treatment of stage III and inflammatory breast cancer (M. D. Anderson Cancer Center experience). Surg Oncol Clin North Am. 1995;4:715–734
  68. Baldini E, Gardin G, Evangelista G, et al. Long-term results of combined-modality therapy for inflammatory breast cancer. Clin Breast Cancer. 2004;5:358–363
  69. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  70. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathological complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000–1006
  71. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the mulitmodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775–1782
  72. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415–419
  73. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1684
  74. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  75. Slamon DJ, Leyland-Jones B, Shak S, et al. Human breast cancer: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001;344:783–792
  76. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–3685
  77. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: A retrospective review of the M. D. Anderson experience. Cancer. 2007;110:1195–1200
  78. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor: Receptor 2postive locally advanced breast cancer. J Clin Oncol. 2006;24:1831–1838
  79. Van Pelt AE, Mohsin S, Elledge RM, et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer. 2003;4:348–353
  80. Limentani SA, Brufsky AM, Erban JK, et al. phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol. 2007;25:1232–1238
  81. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol. 2003;21:46–53
  82. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream ERK1/2 and AKT pathways. Oncogene. 2002;21:6255–6263
  83. Ha B, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305–5313
  84. Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J Clin Oncol. 2006;24(suppl):502
  85. Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat. 2006;55:58;(abstr 1)
  86. Arthur DW, Schmidt-Ullrich RK, Friedman RG, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: Complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999;44:289–296
  87. de Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: Is there a place for surgery?. Ann Oncol. 2000;11:1147–1153
  88. Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonrnetastatic breast cancer. Cancer Res. 1987;47:3889–3894
  89. Hortobagyi G, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In:  Harris JR,  Lippman ME,  Morrow M editor. Treatment of Locally Advanced and Inflammatory Breast Cancer. Philadelphia, PA: Lippincott, Williams Sc Wis; 2000;p. 645–660
  90. Vlastos G, Fomage BD, Mirza NW, et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg. 2000;179:446–452
  91. Fields JN, Perez CA, Kuske RR, et al. Inflammatory carcinoma of the breast: Treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989;17:149–155
  92. Fleming RYD, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4:452–461
  93. Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer-a reassessment of margin status. Ann Surg Oncol. 1999;6:249–254
  94. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: Effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47:1191–1200
  95. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis. J Clin Oncol. 2005;23:1941–1950
  96. Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851–855
  97. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–1208
  98. Liauw SL, Benda RK, Morris CG, et al. Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. Cancer. 2004;100:920–928
  99. Chu AM, Cope O, Russo R, et al. Treatment of early stage breast cancer by limited surgery and radical irradiation. Int J Radiat Oncol Biol Phys. 1980;6:25–30
  100. Pisansky TM, Schaid DJ, Loprinzi CL, et al. Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992;15:376–387
  101. Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol. 2006;16:177–185
  102. Cox JD. Chemoradiation for malignant epithelial tumors. Cancer Radiother. 1998;2:7–11
  103. Ethier SP. Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia. 1996;1:111–121
  104. Alpaugh ML, Tomlinson JS, Shao ZM, et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999;59:5079–5084
  105. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61:445–451
  106. Kleer CG, Zhang Y, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002;21:3172–3180

 Supported by Komen Foundation Promise grant KGO81287, the University of Texas Institutional Research grants K12-5611B through the University of Texas Health Sciences Centre from the National Institute of Health, and the University of Texas M. D. Anderson Cancer Center grant no. R01CA138239-01; IRG.

PII: S1053-4296(09)00045-9

doi: 10.1016/j.semradonc.2009.05.008

Seminars in Radiation Oncology
Volume 19, Issue 4 , Pages 256-265 , October 2009

Article Tools

* Image Usage & Resolution